4-ETHYL-CYCLOHEXYLAMINE | 23775-39-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-ETHYL-CYCLOHEXYLAMINE
• 英文别名: trans-4-ethylcyclohexanamine；cis-4-ethylcyclohexanamine；cis-4-ethylcyclohexylamine；4-ethylcyclohexylamine；cis-4-Ethylclohexylamin
• CAS: 23775-39-5
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: IKQCKANHUYSABG-OCAPTIKFSA-N

物化性质

• 沸点：
  75 °C
• 密度：
  0.86

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.02
• 氢给体数：
  1.0
• 氢受体数：
  1.0

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,C
• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  4-ETHYL-CYCLOHEXYLAMINE 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成
  参考文献：
  名称：

  Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

  摘要：

  Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.

  DOI：

  10.1021/acs.jmedchem.9b01852
• 作为产物：
  描述：

  (1s,4s)-N-benzyl-4-ethylcyclohexan-1-amine 在 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 生成 4-ETHYL-CYCLOHEXYLAMINE
  参考文献：
  名称：

  Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

  摘要：

  Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.

  DOI：

  10.1021/acs.jmedchem.9b01852

文献信息

• The Rhodium Catalysed Direct Conversion of Phenols to Primary Cyclohexylamines
  作者：Patrick Tomkins、Carlot Valgaeren、Koen Adriaensen、Thomas Cuypers、Dirk E. De Vos

  DOI：10.1002/cctc.201800486

  日期：2018.9.7

  Cyclohexylamines are important intermediates in chemical industry, which are currently produced from petrochemical sources. Phenols, however, are an attractive sustainable feedstock. We here demonstrate the transformation of phenols with ammonia to primary cyclohexylamines. In contrast to previously reported chemistry which used palladium catalysts, we here show that rhodium is an excellent catalyst

  环己胺是化学工业中的重要中间体，目前是从石油化学来源生产的。但是，苯酚是一种有吸引力的可持续原料。我们在这里证明了苯酚与氨到伯环己胺的转化。与先前报道的使用钯催化剂的化学方法相反，我们在此表明​​铑是形成伯环己胺的极好催化剂。研究了不同的参数，结果表明该反应适用于提供高选择性的酚类化合物。
• [EN] TREATMENT OF CHAGAS DISEASE<br/>[FR] TRAITEMENT DE LA MALADIE DE CHAGAS
  申请人：UNIV DUNDEE

  公开号：WO2015189595A1

  公开（公告）日：2015-12-17

  The invention provides compounds of the formula: wherein L1 and L2 are independently selected from O and S; R1 is C3-C6straight or branched alkyl, C3-C7cycloalkyl, C5-C7cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of which being optionally substituted; R2 is H, methyl or ethyl; R5 is NRxCORy, NRxRy, CH2COCH3, CH2C≡N, or a 5- or 6-membered heteroaryl group which is optionally substituted; X, Y and Z are independently N or CH; Rx is independently H or C1-C4alkyl; Ry is independently H, CrC4alkyl, phenyl or benzyl, either of which is optionally substituted; n is 0-3; salts, hydrates and N-oxides, wherein the optional substituents are further defined in the claims. The compounds have utility in the prophylaxis or treatment of trypanosomal diseases, such as T. cruzi (Chagas disease).

  该发明提供了以下式的化合物：其中L1和L2分别选自O和S；R1为C3-C6直链或支链烷基，C3-C7环烷基，C5-C7环烯基，脱氢胆固醇，苯基或饱和杂环烷基，其中任一可选择地被取代；R2为H，甲基或乙基；R5为NRxCORy，NRxRy，CH2COCH3，CH2C≡N，或者是可选择地被取代的5-或6-成员杂芳基团；X、Y和Z分别为N或CH；Rx分别为H或C1-C4烷基；Ry分别为H，CrC4烷基，苯基或苄基，其中任一可选择地被取代；n为0-3；盐、水合物和N-氧化物，其中可选择的取代基在权利要求中进一步定义。这些化合物在预防或治疗锥虫病等锥虫病方面具有用途。
• Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy
  作者：Kin Sing Stephen Lee、Jun-Yan Liu、Karen M. Wagner、Svetlana Pakhomova、Hua Dong、Christophe Morisseau、Samuel H. Fu、Jun Yang、Peng Wang、Arzu Ulu、Christina A. Mate、Long V. Nguyen、Sung Hee Hwang、Matthew L. Edin、Alexandria A. Mara、Heike Wulff、Marcia E. Newcomer、Darryl C. Zeldin、Bruce D. Hammock

  DOI：10.1021/jm500694p

  日期：2014.8.28

  inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents. In this report, we describe a series of newly synthesized sEH inhibitors with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors. These inhibitors also have better physical properties and optimized pharmacokinetic

  糖尿病正在影响数百万人的生活。大部分糖尿病患者患有严重的并发症，例如神经性疼痛，目前对这些并发症的治疗具有有害的副作用。因此，需要替代治疗策略。最近，通过抑制可溶性环氧化物水解酶 (sEH) 升高环氧脂肪酸被证明可以减轻啮齿动物的糖尿病性神经性疼痛。在本报告中，我们描述了一系列新合成的 sEH 抑制剂，与之前报道的抑制剂相比，它们在人和啮齿动物 sEH 酶内的效力至少高出 5 倍，停留时间也增加了一倍。这些抑制剂还具有更好的物理特性和优化的药代动力学特征。与批准的药物加巴喷丁和先前公布的 sEH 抑制剂相比，从这个新系列中选出的优化抑制剂在缓解糖尿病神经性大鼠疼痛感知方面的功效提高了近 10 倍。因此，这些新的 sEH 抑制剂可能是治疗人类糖尿病神经病变的一种有吸引力的替代方法。
• The preparation of cis- and trans-1-alkyl-4-phthalimidocyclohexanes
  作者：H. Booth、G. C. Gidley、P. R. Thornburrow

  DOI：10.1039/j29710001047

  日期：——

  Mixtures of cis- and trans-4-alkylcyclohexylamines (alkyl = methyl, ethyl, isopropyl, s-butyl, cyclohexyl, and t-butyl) have been prepared by standard methods and have been converted into stereochemically pure cis- and trans-1-alkyl-4-phthalimidocyclohexanes.

  顺式和反式-4-烷基环己胺（烷基=甲基，乙基，异丙基，仲丁基，环己基和叔丁基）的混合物已通过标准方法制备，并已转化为立体化学纯的顺式和反式-1-烷基-4-邻苯二甲酰亚胺基环己烷。
• AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BRAUN Alain

  公开号：US20070191364A1

  公开（公告）日：2007-08-16

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment and in the prevention of obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及公式（I）所定义的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗和预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。